Aurobindo Pharma gets USFDA nod for generic of Pfizer's Revatio

Published On 2015-11-22 09:52 GMT   |   Update On 2023-10-18 09:47 GMT
Advertisement
New Delhi: Aurobindo Pharma today received final approval from the USFDA to manufacture and market generic version of Pfizer's Revatio (sildenafil citrate) tablets used in the treatment of high blood pressure in lungs.

"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sildenafil Tablets, 20 mg", Aurobindo Pharma said in a BSE filing.
Advertisement

The product is expected to be launched in the fourth quarter of the current fiscal, the statement said.

"The approved Abbreviated New Drug Application (ANDA) is bioequivalent and therapeutically equivalent to Pfizer's Revatio Tablets 20 mg", the company added.

Sildenafil Tablets are used in the treatment of pulmonary arterial hypertension (high blood pressure in the lungs).

Quoting IMS data, Aurobindo Pharma said the approved product has an estimated market size of USD 80 million for the twelve months ended September 2015.

This is the 51st ANDA to be approved out of Unit VII formulation facility in Hyderabad for manufacturing Oral Non-Antibiotic products, the company added.

Aurobindo now has a total of 219 ANDA approvals from the USFDA.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News